Pre-Conference Workshop Day
Tuesday, June 15
9.00am - 3.00pm EDT I 6.00am - 12.00pm PDT

9.00-10.00 Welcome & Virtual Morning Coffee

Workshop A - Exploring the Utility of Gene Activation Technologies for
Therapeutic Application in Diseases

Tuesday, June 15 | 10.00-12.00

siRNAs have now become an established technology for down regulating gene expression, but in diseases driven by reduced protein expression the opposite approach is required. Small activating RNAs (saRNAs) are chemically similar to siRNA but bind at the target gene promoter to upregulate gene expression. They represent an emerging technology to achieve this goal, building off the success and knowledge gained with siRNAs. Here, we explore the mechanism of saRNAs, the opportunities and challenges in a number of disease settings and discuss how they compare to other gene activation/replacement approaches such as CRSIPRa, mRNA therapeutics and gene therapy.
• Mechanism of saRNA therapeutics for gene activation
• Utility of saRNAs in a range of disease settings
• Discussion on the advantages/disadvantages of the technology vs alternative gene activation/replacement approaches

Workshop Leaders

David Blakey, MiNa

David Blakey
SVP Strategic
MiNa Therapeutics

Matthew Catley, MiNa Therpeutics

Matt Catley
Research Director
MiNa Therapeutics

Jon Voutila, MiNa

Jon Voutila
Senior Research Scientist
MiNa Therapeutics

Agnes Rafalko, MiNa

Agnes Rafalko
Research Director
MiNa Therapeutics

12.00-1.00 Lunch Break & Virtual Networking

Workshop B - RNAi, COVID-19 & Vaccine Development: What Have We Learnt from mRNA Vaccine Development & What Can We Employ for Future Vaccine Development?
Tuesday, June 15 | 1.00-3.00

RNA, in recent days, have proven a global, life-changing drug development modality and advances in RNA related mechanisms provide an invaluable knowledge base. With this, it is vital we reflect and continue to learn about the potential of RNA as a critical tool for the development of therapeutics and vaccines. Chimeron Bio's unique RNA delivery platform leverages a novel self-amplifying RNA technology towards the development of efficacious, low-dose, affordable and globally accessible vaccines and drugs. In addition to COVID-19 vaccine development, Chimeron’s experience in developing first-in-class oncology vaccines and other innovative drug designs maximizing the potential of mRNA and interfering RNA, can provide critical learning opportunities. Here, we will reflect on next-generation technology for vaccine development and discuss the advantages of employing RNA to address various diseases.

  • Explore Chimeron Bio's unique approach to vaccine development and the applicability across different diseases
  • What are the advantages we can expect over the current leading technologies?
  • Discuss the innovation underlying the combination of mRNA and interfering RNA for effective drug design across therapeutic areas
  • Evaluate the current data and how this ultimately showcases the potential of RNA for vaccines and therapeutics.

Jolly Mazumdar, Chimeron

Jolly Mazumdar


Thimmaiah Chendrimada
Chief Scientific Officer

Jeff U

Jeffrey Ulmer
Vaccines Key Opinion Leader

3.00 End of Pre-Conference Workshop Day